At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 12,000 target
Drug / intervention
Pemetrexed plus Pembrolizumab +2 moredrug
Likely dose
Pemetrexed plus Pembrolizumab 1200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05055908Phase 3RecruitingUpdate OverdueUpdated 22mo ago · Completion was 12mo agoEnrollment Stalled
Long Recruiting
Update Overdue
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors With or Without Chemotherapy
In Brief
A Phase 3 clinical trial evaluating Pemetrexed plus Pembrolizumab, Pembrolizumab, and 1 other intervention for Lung Cancer. Currently recruiting, targeting 12,000 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesChina
Collaborators--
Timeline
Phase 3Recruiting
202220232024202520262027
First PostedSep 2021
Enrollment StartOct 2021
Primary CompletionJul 2025
TodayJul 2026
Study CompletionSep 2027
First PostedSep 24, 2021
Enrollment StartOct 1, 2021
Primary CompletionJul 1, 2025
Study CompletionSep 14, 2027
TodayJul 1, 2026
Enrollment to primary: 3.8 yearsPosted 4.8 years ago
Interventions
Pemetrexed plus Pembrolizumabdrug
Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days
Pembrolizumabdrug
Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.
Pemetrexeddrug
Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.